Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Switzerland / NCT07659769
Recruiting Observational

Global Healthcare Study on Hidradenitis Suppurativa

NCT07659769 · tracked via the Priya Life Science Switzerland tracker
Sponsor
Julia Tatjana Maul
Phase
Observational
Started
2025-01-01
Last updated
2026-09-28

Condition(s) studied

Hidradenitis Suppurativa (HS)Hidradenitis Suppurativa (Acne Inversa)

Study summary

The Global Healthcare Study on Hidradenitis Suppurativa (GHSHS) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with hidradenitis suppurativa. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.

Eligibility

Sex
ALL
Min age
14 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Signed General Consent Form, or equivalent document * Confirmed diagnosis of Hidradenitis Suppurativa Exclusion Criteria: * Inability to provide informed consent. * Datasets with ambiguous or unclear diagnosis.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Zurich Zurich Switzerland Recruiting

More Julia Tatjana Maul trials in Switzerland

Global Healthcare Study on Atopic Dermatitis Recruiting
Global Healthcare Study on Psoriasis Recruiting

Other trials for the same condition

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07659769 on ClinicalTrials.gov ↗ ← All trials in Switzerland